Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.99M Buy
413,019
+222,135
+116% +$1.34M 0.02% 832
2026
Q1
$1.18M Buy
190,884
+27,820
+17% +$231K 0.02% 832
2025
Q4
$1.7M Buy
+163,064
New +$1.64M 0.03% 749
2025
Q3
Sell
-280,135
Closed -$3.64M 1314
2025
Q2
$3.64M Buy
280,135
+141,072
+101% +$2.12M 0.08% 435
2025
Q1
$3.51M Buy
139,063
+55,533
+66% +$1.65M 0.09% 402
2024
Q4
$2.87M Buy
83,530
+19,382
+30% +$874K 0.07% 485
2024
Q3
$3.17M Buy
64,148
+22,792
+55% +$1.17M 0.09% 412
2024
Q2
$2.49M Buy
+41,356
New +$2.36M 0.08% 399

Other funds holding RXST

Algert Global's RXST Position: Q2 2026 in Review

Algert Global increased its RxSight (RXST) stake by 116% in Q2 2026, buying an estimated $1.34M and bringing the position to 413,019 shares worth $1.99M. The position accounts for 0.02% of the portfolio, ranked #832.

Algert Global first reported a position in RXST in Q2 2024 and has held it in 8 quarters since. The position peaked at $3.64M in Q2 2025. 152 funds tracked by Wall St. Rank hold RXST as of Q2 2026.

  • Algert Global held 413,019 shares of RxSight worth $1.99M as of Q2 2026.
  • Algert Global bought 222,135 RxSight shares in Q2 2026, an estimated $1.34M.
  • RxSight made up 0.02% of Algert Global's portfolio in Q2 2026, its #832 holding.
  • Algert Global first reported a position in RxSight in Q2 2024 and has held it in 8 quarters since.
  • Algert Global's RxSight position peaked at $3.64M in Q2 2025.
  • 152 funds tracked by Wall St. Rank held RxSight as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.